Review of the Role of HER2/neu in Colorectal Carcinomas

被引：3
作者：
Achalla, Lakshmi Sai Vijay [1 ]
Shinde, Raju K. [2 ]
Jogdand, Sangita [3 ]
Vodithala, Sahitya [4 ]
机构：
[1] Datta Meghe Inst Med Sci DMIMS, Jawaharlal Nehru Med Coll JNMC, Dept Surg, Acharya Vinoba Bhave Rural Hosp AVBRH, Wardha, India
[2] Datta Meghe Inst Med Sci DMIMS Univ, Dept Gen Surg, Wardha, India
[3] Jawaharlal Nehru Med Coll JNMC, Dept Pharmacol, Dana Meghe Inst Med Sci DMIMS, Acharya Vinoba Bhave Rural Hosp AVBRH, Wardha, India
[4] Jawaharlal Nehru Med Coll JNMC, Dept Pathol & Lab Med, Acharya Vinoba Bhave Rural Hosp AVBRH, Datta Meghe Inst Med Sci DMIMS, Wardha, India
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 05期
关键词：
mcrc; immunohistochemistry; trastuzumab; her2/neu; colorectal cancer; CANCER; OVEREXPRESSION; AMPLIFICATION; THERAPY; DISTAL;
D O I：
10.7759/cureus.25409
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human epidermal growth factor receptor 2 (HER2/neu) is an oncogenic driver and a proven target for treatment of breast and gastric cancers. The role of HER2/neu and its blockage in various tumors, particularly colorectal adenocarcinoma has been widely explored following the revolutionary impact of anti-HER2/neu therapy in breast and gastric carcinoma patients. This review aimed to highlight the most recent updates on the significance of HER2/neu as a prognostic and predictive factor in these tumors together with its subsequent possible therapeutic indications from predinical tests and ongoing assessments testing anti-HER2/neu agents in colorectal carcinoma (CRC). In the near future with a growingly tailored therapeutic approach toward cancers, HER2/neu targeted therapeutic strategies may blend into CRC treatment methods.
引用
收藏
页数：6
相关论文
共 38 条
[1]  
[Anonymous], 2003, Onkologie
[2]  
[Anonymous], 2016, ANN ONCOL, DOI DOI 10.1093/ANNONC/MDW370.08
[3]  
Bang YJ, 2010, LANCET, V376, P1302
[4]   A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer [J].
Bertotti, Andrea ;
Migliardi, Giorgia ;
Galimi, Francesco ;
Sassi, Francesco ;
Torti, Davide ;
Isella, Claudio ;
Cora, Davide ;
Di Nicolantonio, Federica ;
Buscarino, Michela ;
Petti, Consalvo ;
Ribero, Dario ;
Russolillo, Nadia ;
Muratore, Andrea ;
Massucco, Paolo ;
Pisacane, Alberto ;
Molinaro, Luca ;
Valtorta, Emanuele ;
Sartore-Bianchi, Andrea ;
Risio, Mauro ;
Capussotti, Lorenzo ;
Gambacorta, Marcello ;
Siena, Salvatore ;
Medico, Enzo ;
Sapino, Anna ;
Marsoni, Silvia ;
Comoglio, Paolo M. ;
Bardelli, Alberto ;
Trusolino, Livio .
CANCER DISCOVERY, 2011, 1 (06) :508-523
[5]   COLORECTAL-CANCER - EVIDENCE FOR DISTINCT GENETIC CATEGORIES BASED ON PROXIMAL OR DISTAL TUMOR LOCATION [J].
BUFILL, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (10) :779-788
[6]   Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer [J].
Guarini, Chiara ;
Grassi, Teresa ;
Pezzicoli, Gaetano ;
Porta, Camillo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
[7]   Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine [J].
Haslem, Derrick S. ;
Ji, Hanlee P. ;
Ford, James M. ;
Nadauld, Lincoln D. .
JCO PRECISION ONCOLOGY, 2017, 1 :1-6
[8]   HER2/neu testing in primary colorectal carcinoma [J].
Heppner, B. Ingold ;
Behrens, H-M ;
Balschun, K. ;
Haag, J. ;
Krueger, S. ;
Becker, T. ;
Roecken, C. .
BRITISH JOURNAL OF CANCER, 2014, 111 (10) :1977-1984
[9]   Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer [J].
Hortobagyi, GN .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :43-47
[10]  
Iqbal N., 2014, Mol Biol Int, DOI 10.1155/2014/852748
1234